LearnGlossaryMarketStocksSuperinvestorsSign in

RNXT

RenovoRx, Inc.

Healthcare · $70M market cap

Verdict

We can't put a fair value on RNXT right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-23.3% a year✗
Sales growth—?
Free cash flow growth—?
Return on invested capital-36.9%✗

Follow RNXT

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 10, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Other filings

VOLL MARK

Chief Financial Officer · 2026-09-10

Award

80,000 shares

About RenovoRx, Inc.

RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works